SLC25A39 and prostate adenocarcinoma: The expression levels of ABHD11, GSTZ1, NTHL1, PTRH2, and SLC25A39 were notably up-regulated in PRAD samples (p < 0.05), Conversely, the expression of CAT and OXR1 was down-regulated in the PRAD cohort (Fig. 8C).